Abstract #0076

Gadoxetate-enhanced abbreviated MRI is reliable and effective for HCC surveillance in high-risk patients.

Ryan L Brunsing¹, Dennis Chen¹, Alexandra Schlein¹, Paul Murphy², Yesenia Covarrubias¹, Alex Kuo³, Michel Mendler⁴, Irene Vodkin⁴, Rohit Loomba⁴, Yuko Kono⁴, and Claude B Sirlin¹

¹Liver Imaging Group, University of California San Diego, San Diego, CA, United States, ²Radiology, University of California San Diego, San Diego, CA, United States, ³Gastroenterology and Hepatology, Virginia Mason Medical Center, Seattle, WA, United States, ⁴Hepatology, University of California San Diego, San Diego, CA, United States

Gadoxetate enhanced abbreviated MRI (AMRI) is a simple, rapid acquisition protocol aimed at reducing the cost and increasing the throughput of MRI-based HCC surveillance. Here we analyze 330 consecutive patients with cirrhosis or chronic HBV who underwent at least one screening AMRI. The rate of HCC detected at cross sectional analysis (3.3%) was in line with published incidence of HCC, while the technical failure rate was low (5.8%) despite high prevalence of cirrhosis and ascites. Longitudinal analysis demonstrated high sensitivity, specificity, and negative predictive value in HCC detection, using a composite reference standard.

This abstract and the presentation materials are available to members only; a login is required.

Join Here